Quantum Cyber N.V. Sales And Marketing Expense
Quantum Cyber N.V. (QUCY) reported Sales And Marketing Expense of $2.35 million for the 6-month period ending 2025-06-30, per its 6-K filed 2025-09-26.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:SalesAndMarketingExpense · last filed 2025-09-26
- Quantum Cyber N.V. sales and marketing expense for the quarter ending 2023-12-31 was $950.68K, a 68.34% decline year-over-year.
- Quantum Cyber N.V. sales and marketing expense for the quarter ending 2023-09-30 was $1.12M, a 85.22% increase year-over-year.
- Quantum Cyber N.V. sales and marketing expense for the quarter ending 2023-06-30 was $1.80M, a 3.58% decline year-over-year.
- Quantum Cyber N.V. sales and marketing expense for the quarter ending 2023-03-31 was $2.41M, a 161.59% increase year-over-year.
| Period end | Sales And Marketing Expense 3 month | Sales And Marketing Expense 6 month | Sales And Marketing Expense 6 month as first filed | Sales And Marketing Expense 9 month | Sales And Marketing Expense 12 month | Sales And Marketing Expense 12 month as first filed |
|---|---|---|---|---|---|---|
| 2025-06-30 | $2.35M 6-K · filed 2025-09-26 | |||||
| 2024-12-31 | $6.58M 20-F · filed 2025-03-31 | |||||
| 2024-06-30 | $2.36M 6-K · filed 2025-09-26 | |||||
| 2023-12-31 | $950.68K derived: 20-F 12 month − 6-K 9 month · filed 2025-03-31 | $2.07M derived: sum of 2 quarters · filed 2025-03-31 | $3.87M derived: sum of 3 quarters · filed 2025-03-31 | $6.16M 20-F · filed 2025-03-31 | ||
| 2023-09-30 | $1.12M 6-K · filed 2023-11-16 | $2.92M derived: sum of 2 quarters · filed 2023-11-16 | $5.21M 6-K · filed 2023-11-16 | $8.34M derived: sum of 4 quarters · filed 2025-03-31 | ||
| 2023-06-30 | $1.80M 6-K · filed 2023-08-15 | $3.99M 6-K · filed 2024-10-18 | $4.09M 6-K · filed 2023-08-15 | $7.21M derived: sum of 3 quarters · filed 2025-03-31 | $7.82M derived: sum of 4 quarters · filed 2025-03-31 | |
| 2023-03-31 | $2.41M 6-K · filed 2023-05-16 | $5.41M derived: sum of 2 quarters · filed 2025-03-31 | $6.02M derived: sum of 3 quarters · filed 2025-03-31 | $7.89M derived: sum of 4 quarters · filed 2025-03-31 | ||
| 2022-12-31 | $3.00M derived: 20-F 12 month − 6-K 9 month · filed 2025-03-31 | $3.61M derived: sum of 2 quarters · filed 2025-03-31 | $5.48M derived: sum of 3 quarters · filed 2025-03-31 | $6.40M 20-F · filed 2025-03-31 | $5.70M 20-F · filed 2023-04-07 | |
| 2022-09-30 | $605.84K 6-K · filed 2023-11-16 | $2.47M derived: sum of 2 quarters · filed 2023-11-16 | $3.39M 6-K · filed 2023-11-16 | |||
| 2022-06-30 | $1.87M 6-K · filed 2023-08-15 | $2.79M 6-K · filed 2023-08-15 | $2.52M 6-K · filed 2022-09-07 | |||
| 2022-03-31 | $921.63K 6-K · filed 2023-05-16 | |||||
| 2021-12-31 | $962.66K 20-F · filed 2024-04-09 | $957.52K 20-F · filed 2022-05-03 | ||||
| 2021-06-30 | $150.34K 6-K · filed 2022-09-07 | |||||
| 2020-12-31 | $110.38K 20-F · filed 2023-04-07 | |||||
| 2019-12-31 | $181.46K 20-F · filed 2022-05-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |